Dalibor Valík

Learn More
Currently, there are no effective biomarkers for ovarian cancer prognosis or prediction of therapeutic response. The objective of this study was to examine a panel of 10 serum biochemical parameters for their ability to predict response to chemotherapy, progression and survival of ovarian cancer patients. Sera from ovarian cancer patients were collected(More)
INTRODUCTION Microarray-based gene expression profiling represents a major breakthrough for understanding the molecular complexity of breast cancer. cDNA expression profiles cannot detect changes in activities that arise from post-translational modifications, however, and therefore do not provide a complete picture of all biologically important changes that(More)
Research has exposed cancer to be a heterogeneous disease with a high degree of inter-tumoral and intra-tumoral variability. Individual tumors have unique profiles, and these molecular signatures make the use of traditional histology-based treatments problematic. The conventional diagnostic categories, while necessary for care, thwart the use of molecular(More)
detection introduced the possibility of early targeted antimicrobial treatment that, in turn, may improve the outcome of patients with sepsis [1]. We retrospectively evaluated 54 results of the SeptiFast test from patients with solid malignancy admitted to the ICU between June 2009 and August 2011. Specimens from suspected bloodstream infection were(More)
B-cell activating factor (BAFF) is a cytokine and adipokine of the TNF ligand superfamily. The main biological function of BAFF in maintaining the maturation of B-cells to plasma cells has recently made it a target of the first FDA-approved selective BAFF antibody, belimumab, for the therapy of systemic lupus erythematosus. Concomitantly, the role of BAFF(More)
BACKGROUND The aim of the present retrospective study was to analyze clinical outcome and risk factors associated with treatment outcomes according to KRAS status in patient with metastatic colorectal cancer (mCRC) treated with bevacizumab (bev) plus chemotherapy in the first-line setting. METHODS We performed observational study on 1622 patients with(More)
Dr Kirkwood suggests that there are a number of 'errors' in the editorial, but provides no evidence for these, although there is a difference in our interpretations of the available data, which is incomplete. In the absence of the definitive report on E1690 it is reasonable to speculate that stage migration and changes in surgical technique might explain(More)
Adenylosuccinate lyase (ASL) deficiency is a defect in purine de novo synthesis pathway. The disease has variable clinical presentation involving psychomotor retardation, seizures, hypotonia, and autism. The presence of succinyladenosine and succinylaminoimidazole carboxamide riboside (SAICA riboside) in body fluids characterizes the biochemical phenotype.(More)
Genetic counseling of high-risk cancer families was started one and a half years ago in Masaryk Memorial Cancer Institute in Brno, the second largest city in the Czech Republic located in South Moravia. Since that time more than 120 families, mostly with breast/ovarian or colorectal cancers were seen. The inheritance and the possibilities of cancer(More)